Healthcare provider profile · identity verified

Mark M. Bai, MD

Family Practice · FONTANA, CA · NPI 1336216217

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	428	268
Amlodipine Besylate	Amlodipine Besylate	280	173
Rosuvastatin Calcium	Rosuvastatin Calcium	233	126
Metformin Hcl	Metformin Hcl	224	143
Lisinopril	Lisinopril	221	137
Losartan Potassium	Losartan Potassium	203	130
Levothyroxine Sodium	Levothyroxine Sodium	178	100
Glipizide	Glipizide	124	78
Omeprazole	Omeprazole	123	81
Pantoprazole Sodium	Pantoprazole Sodium	121	85
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	102	52
Albuterol Sulfate Hfa	Albuterol Sulfate	95	67
Atenolol	Atenolol	92	51
Meloxicam	Meloxicam	88	66
Gabapentin	Gabapentin	79	50
Alendronate Sodium	Alendronate Sodium	78	42
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	76	35
Metformin Hcl Er	Metformin Hcl	76	56
Simvastatin	Simvastatin	76	51
Bisoprolol Fumarate	Bisoprolol Fumarate	72	30
Tamsulosin Hcl	Tamsulosin Hcl	72	44
Hydrochlorothiazide	Hydrochlorothiazide	66	47
Ibuprofen	Ibuprofen	65	48
Metoprolol Tartrate	Metoprolol Tartrate	61	42
Potassium Chloride	Potassium Chloride	61	51
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	60	11
Terazosin Hcl	Terazosin Hcl	55	34
Jardiance	Empagliflozin	49	34
Pradaxa	Dabigatran Etexilate Mesylate	49	33
Trazodone Hcl	Trazodone Hcl	47	25
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	44	28
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	37	15
Ozempic	Semaglutide	35	20
Famotidine	Famotidine	33	20
Fluticasone Propionate	Fluticasone Propionate	33	17
Sertraline Hcl	Sertraline Hcl	33	22
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	32	27
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	31	30
Ezetimibe	Ezetimibe	30	18
Furosemide	Furosemide	30	26
Spironolactone	Spironolactone	30	18
Triamcinolone Acetonide	Triamcinolone Acetonide	29	25
Allopurinol	Allopurinol	28	16
Humulin N	Insulin Nph Human Isophane	28	18
Colchicine	Colchicine	27	19
Acyclovir	Acyclovir	26	12
Duloxetine Hcl	Duloxetine Hcl	26	11
Metoprolol Succinate	Metoprolol Succinate	26	13
Humulin R	Insulin Regular, Human	25	14
Lactulose	Lactulose	24	17
Azelastine Hcl	Azelastine Hcl	22	suppressed
Carvedilol	Carvedilol	22	15
Finasteride	Finasteride	22	16
Fluoxetine Hcl	Fluoxetine Hcl	22	14
Hydrocortisone	Hydrocortisone	21	12
Wixela Inhub	Fluticasone Propion/Salmeterol	21	16
Citalopram Hbr	Citalopram Hydrobromide	20	suppressed
Clopidogrel	Clopidogrel Bisulfate	20	16
Hydralazine Hcl	Hydralazine Hcl	20	16
Nitroglycerin	Nitroglycerin	19	13
Naproxen	Naproxen	18	14
Lovastatin	Lovastatin	17	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	17	12
Arexvy	Rsvpref3 Antigen/As01e/Pf	16	16
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	15	15
Doxycycline Monohydrate	Doxycycline Monohydrate	15	12
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	15	12
Montelukast Sodium	Montelukast Sodium	15	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Alvesco	Ciclesonide	14	suppressed
Cefadroxil	Cefadroxil	14	14
Ondansetron Odt	Ondansetron	14	12
Spiriva Respimat	Tiotropium Bromide	14	12
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	11
Venlafaxine Hcl Er	Venlafaxine Hcl	13	11
Mupirocin	Mupirocin	12	suppressed
Nystatin	Nystatin	12	12
Testosterone	Testosterone	12	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	12	suppressed
Cephalexin	Cephalexin	11	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error